Core Viewpoint - DexCom Inc. is identified as a promising growth stock in the NASDAQ for the next five years, despite a recent price target reduction by Truist analyst Richard Newitter from $102 to $94 while maintaining a Buy rating [1][2]. Group 1: Company Overview - DexCom Inc. specializes in designing, developing, and commercializing continuous glucose monitoring (CGM) systems both in the US and internationally [3]. Group 2: Market Outlook - Truist anticipates healthy revenue and earnings for Q3 2025 across the MedTech sector, although it warns of potential stock volatility [1]. - Stifel has resumed coverage on several MedTech companies, citing an optimistic outlook for sector growth driven by the adoption of CGMs and insulin pumps, particularly highlighting long-term growth opportunities in the CGM market for Type 2 Basal-only and Type 2 Non-insulin patient segments [2].

Core Viewpoint - DexCom's shares have underperformed the broader market in 2025, down 11% year to date, primarily due to legal and regulatory challenges impacting its performance [1][8] Financial Performance - Despite the stock's decline, DexCom's financial results have been strong, with expectations for continued growth in the upcoming quarterly update on October 30 [2][6] - The company's guidance for fiscal 2025 indicates a year-over-year revenue growth of approximately 14% to 15%, which is critical for maintaining investor confidence [6] Product and Market Position - DexCom is a leading player in the continuous glucose monitoring (CGM) market, with its latest device, the G7, launched in the U.S. in 2023 [3][7] - Some patients have reported issues with inaccurate readings from the G7 device, leading to class action lawsuits, although the majority of customers are still using older G6 devices [4][6] Regulatory Challenges - The company received a warning letter from the U.S. Food and Drug Administration regarding manufacturing issues, which negatively impacted its stock price [5][8] - Monitoring how DexCom addresses these regulatory challenges will be crucial in the upcoming quarterly update [6] Competitive Landscape - DexCom faces competition from Abbott Laboratories, which has also experienced quality control issues with its FreeStyle Libre device, yet remains a significant growth driver for Abbott [7]

NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired DexCom securitie ...

Core Insights - DexCom (DXCM) is expected to report quarterly earnings of $0.57 per share, reflecting a 26.7% increase year-over-year, with revenues projected at $1.18 billion, an 18.4% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 0.8% in the last 30 days, indicating a reassessment by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Revenue Projections - Analysts estimate 'Revenue- Hardware' to be $39.65 million, showing a year-over-year decline of 6.5% [4]. - 'Revenue- Sensor and other' is projected at $1.14 billion, indicating a 19.6% increase from the year-ago quarter [5]. - 'Revenue- United States' is expected to reach $843.25 million, reflecting a 20.1% year-over-year increase [5]. - 'Revenue- International' is forecasted at $332.15 million, suggesting a 13.6% increase compared to the previous year [5]. Stock Performance - Over the past month, DexCom shares have returned 2.9%, while the Zacks S&P 500 composite has increased by 3.8% [6]. - Currently, DexCom holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the overall market in the near future [6].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit against DexCom, Inc. on behalf of shareholders who purchased securities between July 26, 2024, and September 17, 2025, alleging that the company misled investors regarding its business operations [1][2]. Allegations - The lawsuit claims that DexCom made unauthorized material design changes to its G6 and G7 continuous glucose monitoring systems, which rendered them less reliable and posed health risks to users [3]. - It is alleged that the enhancements to the G7 device were overstated, and the company downplayed the severity of issues related to the G7 devices [3]. - The lawsuit suggests that these actions increased DexCom's risk of regulatory scrutiny and potential legal, reputational, and financial harm [3]. - Investors reportedly suffered damages when the true details about the devices were revealed [3]. Next Steps for Shareholders - Shareholders wishing to serve as lead plaintiffs must file motions with the court by December 29, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. About Rosen Law Firm - Rosen Law Firm is recognized for its commitment to shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [6].

Core Viewpoint - DexCom, Inc. is facing a class action lawsuit alleging that the company made materially false and misleading statements regarding its G6 and G7 devices, which may have health risks for users [3]. Group 1: Lawsuit Details - The class action is on behalf of investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, with a deadline of December 26, 2025, for filing a lead plaintiff motion [1]. - Allegations include unauthorized design changes to the G6 and G7 devices that compromised their reliability and safety, posing health risks to users [3]. - The lawsuit claims that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues related to the devices [3]. Group 2: Legal Representation - The Portnoy Law Firm is representing investors in this case and offers complimentary case evaluations to discuss options for recovering losses [2][4]. - The founding partner of the Portnoy Law Firm has a track record of recovering over $5.5 billion for investors affected by corporate wrongdoing [4].

Core Insights - DexCom Inc is under scrutiny following reports of three deaths linked to its G7 continuous glucose monitor, raising safety concerns about the device [1][4]. - An investigation by Hunterbrook criticized DexCom for failing to ensure the accuracy and reliability of the G7 device, with reports of severe complications among patients [2]. - Class action lawsuits have been filed against DexCom, alleging misleading information regarding the accuracy of its monitoring system [3]. Regulatory and Legal Issues - The FDA's MAUDE database has recorded at least 13 deaths associated with the G7 since its launch in 2023, highlighting ongoing safety issues [5]. - A warning letter was issued to DexCom by the FDA in March 2025, citing potential sensor malfunctions and communication errors [6]. - Legal actions include class action lawsuits and a separate securities lawsuit filed against the company [3]. Market Performance - DexCom's stock has seen a decline, with shares down 2.87% to $68.59 at the time of publication [6].

Core Viewpoint - A securities class action lawsuit has been filed against DexCom, Inc. for allegedly making false statements and failing to disclose material design changes to its G6 and G7 devices, which may have compromised their reliability and safety [1][2]. Group 1: Allegations Against DexCom - The lawsuit claims that DexCom made unauthorized material design changes to the G6 and G7 devices, which were not approved by the U.S. Food and Drug Administration (FDA) [2]. - These design changes reportedly rendered the G6 and G7 devices less reliable than previous versions, posing a significant health risk to users who depend on accurate glucose readings [2]. - The enhancements claimed by DexCom for the G7 device, including its reliability, accuracy, and functionality, were allegedly overstated [2]. - The company is accused of downplaying the severity of issues and health risks associated with the altered G7 devices [2]. - As a result of these actions, DexCom faces increased regulatory scrutiny and potential legal, reputational, and financial harm [2]. - The public statements made by DexCom were claimed to be materially false and misleading throughout the relevant period [2]. Group 2: Investor Information - Investors who acquired DexCom shares during the class period (July 26, 2024, to September 17, 2025) are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on December 26, 2025 [3].

Core Viewpoint - DexCom, Inc. is expected to report strong third-quarter results, driven by operational momentum, patient growth, and improved access, with a raised full-year revenue outlook reflecting confidence in demand and reimbursement expansion [1][2][8] Operational Performance - The company enters Q3 with solid operational momentum, supported by continued patient growth and a strengthening global footprint [2][8] - Commercial execution is a focal point, with healthy uptake of the product portfolio, particularly G7 and Stelo, despite competitive pressures [3][8] - Improved channel operations and access expansion are likely to have contributed to stronger prescription trends and pharmacy channel throughput [4][6] U.S. Market Dynamics - Strong new patient additions and integration with over 100 health systems have supported smoother prescription workflows [4][5] - Coverage for Type 2 diabetes patients not on insulin has broadened, with access secured through a major PBM, potentially covering around six million lives [4][5] International Trends - The international business has maintained healthy growth, driven by expanding Type 2 access and market penetration in regions like Ontario, France, and Japan [7][10] - Management expects continued international contribution, supported by growing awareness among primary care providers and improving prescription visibility [9][10] Stelo and New Market Initiatives - Stelo is an emerging growth vector, with over 400,000 app downloads and partnerships enhancing user engagement [11][12] - While currently a small financial contributor, Stelo is expected to represent 2% to 3% of 2025 sales, with ongoing feature expansion likely to accelerate adoption [12] Financial Outlook and Margin Progress - The company raised its full-year 2025 revenue outlook to $4.60 to $4.625 billion, reflecting 14% to 15% growth [13] - Gross margin is projected at approximately 62%, with expectations for sequential improvement as freight costs ease and inventory levels normalize [13][14] Estimate Picture - The Zacks Consensus Estimate for Q3 revenues is $1.18 billion, indicating an 18.4% improvement year-over-year, with EPS expected to increase by 26.7% to 57 cents [15] Long-Term Investment Visibility - Dexcom's long-term growth is supported by the expansion of the CGM category into Type 2 and pre-diabetes markets, with improving coverage and digital workflow integration [24][25] - Innovation remains central to the strategy, with advancements in product offerings and software enhancing usability and user engagement [25][26]

Core Points - A shareholder class action lawsuit has been filed against DexCom, alleging that the company made materially false and misleading statements regarding the G6 and G7 devices [1] - The lawsuit claims that DexCom made unauthorized design changes to the G6 and G7, which compromised their reliability and presented health risks to users [1] - The allegations include overstated claims about the enhancements and functionality of the G7, as well as downplaying the severity of issues related to the devices [1] - The lawsuit suggests that these actions have exposed DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [1] Legal Context - Shareholders who purchased DexCom shares between July 26, 2024, and September 17, 2025, and suffered significant losses are encouraged to discuss their legal rights [2] - The deadline for shareholders to request to be appointed as lead plaintiff in the case is December 26, 2025 [3] - Holzer & Holzer, LLC is representing shareholders in this litigation and has a history of recovering significant amounts for investors affected by corporate misconduct [3]